Search Results - "Burden, D."

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials by Reich, K., Burden, A.D., Eaton, J.N., Hawkins, N.S.

“…Summary Background  Ustekinumab, a novel monoclonal antibody for the treatment of moderate to severe plaque‐type psoriasis, has recently received regulatory…”
Get full text

Psoriasis, COVID‐19 and shielding by Becher, G., Burden, A.D.

“…Linked Article: Mahil et al. Br J Dermatol 2021; 185:80–90…”
Get full text

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update by Smith, C.H., Yiu, Z.Z.N., Bale, T., Burden, A.D., Coates, L.C., Edwards, W., MacMahon, E., Mahil, S.K., McGuire, A., Murphy, R., Nelson‐Piercy, C., Owen, C.M., Parslew, R., Uthman, O.A., Woolf, R.T., Manounah, L., Ezejimofor, M.C., Exton, L.S., Mohd Mustapa, M.F.

“…Linked Comment: Ormerod. Br J Dermatol 2020; 183:604. Plain language summary available online…”
Get full text

World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.): Third edition of the guideline for evaluating efficacy of anthelmintics in ruminants (bovine, ovine, caprine) by Burden, D.J., Bartley, D.J., Besier, R.B., Claerebout, E., Elliott, T.P., Höglund, J., Rehbein, S., Torres-Acosta, J.F.J., Van Wyk, J.A., Yazwinski, T.

“…This guideline is aimed at those who are involved in the assessment of anthelmintic efficacy in ruminant livestock species (bovine, ovine and caprine). The…”
Get full text

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) by Mahil, S.K., Wilson, N., Dand, N., Reynolds, N.J., Griffiths, C.E.M., Emsley, R., Marsden, A., Evans, I., Warren, R.B., Stocken, D., Barker, J.N., Burden, A.D., Smith, C.H.

“…Summary Background The ‘treat to target’ paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis…”
Get full text

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 by Smith, C.H., Jabbar‐Lopez, Z.K., Yiu, Z.Z., Bale, T., Burden, A.D., Coates, L.C., Cruickshank, M., Hadoke, T., MacMahon, E., Murphy, R., Nelson‐Piercy, C., Owen, C.M., Parslew, R., Peleva, E., Pottinger, E., Samarasekera, E.J., Stoddart, J., Strudwicke, C., Venning, V. A., Warren, R.B., Exton, L.S., Mohd Mustapa, M.F.

“…Plain language summary available online…”
Get full text

Interlaboratory Study of Digital Volume Correlation Error Due to X-Ray Computed Tomography Equipment and Scan Parameters: an Update from the DVC Challenge by Croom, B.P., Burden, D., Jin, H., Vonk, N.H., Hoefnagels, J.P.M., Smaniotto, B., Hild, F., Quintana, E., Sun, Q., Nie, X., Li, X.

“…Background The quality of Digital Volume Correlation (DVC) full-field displacement measurements depends directly on the characteristics of the X-ray Computed…”
Get full text

Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis by Edward, M, Quinn, JA, Mukherjee, S, Jensen, M. BV, Jardine, AG, Mark, PB, Burden, AD

“…Nephrogenic systemic fibrosis (NSF) is a fibrotic disease generating intense interest due to its recent discovery, and unknown cause. It appears confined to…”
Get full text

The orthodontic condition of children in England, Wales and Northern Ireland 2013 by Rolland, S. L., Treasure, E., Burden, D. J., Fuller, E., Vernazza, C. R.

“…Key Points Highlights that 9% of 12-year-olds and 18% of 15-year-olds were undergoing orthodontic treatment, most with fixed appliances. Shows that 44% of…”
Get full text

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study by Warren, R.B., Marsden, A., Tomenson, B., Mason, K.J., Soliman, M.M., Burden, A.D., Reynolds, N.J., Stocken, D., Emsley, R., Griffiths, C.E.M., Smith, C.

“…Summary Background Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do…”
Get full text

How do you determine the optimal biologic treatment for psoriasis? by Gardner, R., Burden, A.D.

“…Linked Article: Signorovitch et al. Br J Dermatol 2015; 172:504–512…”
Get full text

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis by Mahil, S.K., Ezejimofor, M.C., Exton, L.S., Manounah, L., Burden, A.D., Coates, L.C., Brito, M., McGuire, A., Murphy, R., Owen, C.M., Parslew, R., Woolf, R.T., Yiu, Z.Z.N., Uthman, O.A., Mohd Mustapa, M.F., Smith, C.H.

“…Summary Background The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform…”
Get full text

Ixekizumab in genital psoriasis by Becher, G., Burden, A.D.

“…Linked Article: Ryan et al. Br J Dermatol 2018; 179:844–852…”
Get full text

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study) by Coates, L.C., Aslam, T., Al Balushi, F., Burden, A.D., Burden-The, E., Caperon, A.R., Cerio, R., Chattopadhyay, C., Chinoy, H., Goodfield, M.J.D., Kay, L., Kelly, S., Kirkham, B.W., Lovell, C.R., Marzo-Ortega, H., McHugh, N., Murphy, R., Reynolds, N.J., Smith, C.H., Stewart, E.J.C., Warren, R.B., Waxman, R., Wilson, H.E., Helliwell, P.S.

“…Summary Background  Multiple questionnaires to screen for psoriatic arthritis (PsA) have been developed but the optimal screening questionnaire is unknown…”
Get full text

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives by Burden, A.D., Warren, R.B., Kleyn, C.E., McElhone, K., Smith, C.H., Reynolds, N.J., Ormerod, A.D., Griffiths, C.E.M.

“…Summary Background  The British Association of Dermatologists (BAD) established a web‐based pharmacovigilance register to assess the long‐term safety of…”
Get full text

Exposure to biological therapies during conception and pregnancy: a systematic review by Pottinger, E., Woolf, R.T., Exton, L.S., Burden, A.D., Nelson‐Piercy, C., Smith, C.H.

“…Summary Background Biological therapies are effective treatments for psoriasis and are often prescribed to women of child‐bearing age. Objectives To evaluate…”
Get full text

Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease by Wolf, N, Quaranta, M, Prescott, N J, Allen, M, Smith, R, Burden, A D, Worthington, J, Griffiths, C E M, Mathew, C G, Barker, J N, Capon, F, Trembath, R C

“…Psoriasis is an immune-mediated skin disorder that is inherited as a multifactorial trait. Linkage analyses have clearly mapped a primary disease…”
Get more information

Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) by Iskandar, I.Y.K., Ashcroft, D.M., Warren, R.B., Evans, I., McElhone, K., Owen, C.M., Burden, A.D., Smith, C.H., Reynolds, N.J., Griffiths, C.E.M.

“…Summary Background Treatment modifications, including dose escalations, dose reductions, switches, discontinuations and restarts of biologics may be necessary…”
Get full text

Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE) by Warren, R.B., Barker, J.N.W.B., Finlay, A.Y., Burden, A.D., Kirby, B., Armendariz, Y., Williams, R., Hatchard, C., Khare, S., Griffiths, C.E.M.

“…Summary Background Efficacy data on therapies for patients with psoriasis who have failed tumour necrosis factor (TNF)‐α inhibitor therapy is limited…”
Get full text

Etanercept or infliximab for psoriasis? An independent randomized clinical trial by Burden, A.D.

“…Linked Article: de Vries et al. Br J Dermatol 2017; 176:624–633…”
Get full text